These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37714392)

  • 1. Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development.
    Wang L; Yan Y; Wu L; Peng J
    Pharmacol Res; 2023 Oct; 196():106925. PubMed ID: 37714392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
    Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
    Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy.
    Yao P; Liu Y
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
    Wang J; Yang N; Xu Y
    Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease.
    Tang R; Li R; Li H; Ma XL; Du P; Yu XY; Ren L; Wang LL; Zheng WS
    ACS Nano; 2021 Nov; 15(11):17016-17046. PubMed ID: 34705426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.
    Ni M; Zhang B; Zhao J; Feng Q; Peng J; Hu Y; Zhao Y
    Biomed Pharmacother; 2019 May; 113():108778. PubMed ID: 30897538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment.
    Guo X; Yin X; Liu Z; Wang J
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
    Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
    BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products.
    Xu G; Huang K; Zhou J
    Curr Med Chem; 2018; 25(8):889-907. PubMed ID: 28393690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of Action and Related Natural Regulators of Nrf2 in Nonalcoholic Fatty Liver Disease.
    Yu W; Zhang F; Meng D; Zhang X; Feng Y; Yin G; Liang P; Chen S; Liu H
    Curr Drug Deliv; 2024; 21(10):1300-1319. PubMed ID: 39034715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism and Progress of Natural Products in the Treatment of NAFLD-Related Fibrosis.
    Li JZ; Chen N; Ma N; Li MR
    Molecules; 2023 Dec; 28(23):. PubMed ID: 38067665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver.
    Meng D; Zhang F; Yu W; Zhang X; Yin G; Liang P; Feng Y; Chen S; Liu H
    Diabetes Metab Syndr Obes; 2023; 16():4043-4064. PubMed ID: 38089432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
    Cicero AFG; Colletti A; Bellentani S
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease.
    Liu Q; Zhu L; Cheng C; Hu YY; Feng Q
    Curr Pharm Des; 2017; 23(34):5136-5162. PubMed ID: 28925892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis.
    Li H; Guan T; Qin S; Xu Q; Yin L; Hu Q
    Drug Discov Today; 2023 Mar; 28(3):103471. PubMed ID: 36610488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis.
    Peng A; Liu S; Fang L; Zhu Z; Zhou Y; Yue S; Ma Z; Liu X; Xue S; Qiu Y; Qi R
    Eur J Pharmacol; 2022 Apr; 921():174841. PubMed ID: 35278405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD).
    Kim MS; Kung S; Grewal T; Roufogalis BD
    Curr Pharm Biotechnol; 2012 Feb; 13(2):278-91. PubMed ID: 21470125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.